Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 9 | 2023 | 1852 | 1.560 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2024 | 371 | 1.410 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2023 | 215 | 1.340 |
Why?
|
| Tuberculosis | 4 | 2024 | 505 | 0.960 |
Why?
|
| Neonatology | 1 | 2023 | 51 | 0.840 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 31 | 0.820 |
Why?
|
| Antiprotozoal Agents | 1 | 2022 | 37 | 0.820 |
Why?
|
| Leishmania | 1 | 2022 | 28 | 0.810 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2022 | 48 | 0.810 |
Why?
|
| Leishmaniasis | 1 | 2022 | 33 | 0.810 |
Why?
|
| Apnea | 1 | 2021 | 31 | 0.760 |
Why?
|
| Cyanosis | 1 | 2021 | 41 | 0.760 |
Why?
|
| Eosinophilia | 1 | 2022 | 101 | 0.740 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 271 | 0.720 |
Why?
|
| Maternal Health | 1 | 2020 | 18 | 0.720 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2020 | 25 | 0.700 |
Why?
|
| Hypersensitivity | 1 | 2022 | 182 | 0.700 |
Why?
|
| Malaria | 1 | 2020 | 82 | 0.680 |
Why?
|
| Coinfection | 2 | 2020 | 171 | 0.660 |
Why?
|
| Hookworm Infections | 1 | 2020 | 124 | 0.650 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 236 | 0.640 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 218 | 0.640 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 507 | 0.630 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 229 | 0.620 |
Why?
|
| Family | 1 | 2021 | 571 | 0.580 |
Why?
|
| Community Health Workers | 1 | 2017 | 62 | 0.560 |
Why?
|
| Community Health Services | 1 | 2017 | 88 | 0.550 |
Why?
|
| Education, Distance | 1 | 2017 | 66 | 0.550 |
Why?
|
| Anemia | 1 | 2020 | 340 | 0.540 |
Why?
|
| Parents | 1 | 2023 | 1033 | 0.530 |
Why?
|
| Program Evaluation | 1 | 2017 | 449 | 0.500 |
Why?
|
| Health Personnel | 1 | 2019 | 493 | 0.480 |
Why?
|
| Telemedicine | 1 | 2017 | 426 | 0.380 |
Why?
|
| Social Stigma | 2 | 2021 | 72 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2396 | 0.320 |
Why?
|
| Child | 10 | 2024 | 24247 | 0.300 |
Why?
|
| Humans | 20 | 2024 | 123180 | 0.280 |
Why?
|
| Sputum | 2 | 2024 | 104 | 0.270 |
Why?
|
| Sensitivity and Specificity | 4 | 2024 | 2011 | 0.260 |
Why?
|
| BCG Vaccine | 2 | 2023 | 105 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2024 | 510 | 0.240 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 474 | 0.230 |
Why?
|
| Young Adult | 4 | 2024 | 8864 | 0.230 |
Why?
|
| Adolescent | 7 | 2024 | 19111 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 21 | 0.200 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2022 | 33 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3670 | 0.200 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2022 | 29 | 0.200 |
Why?
|
| Leukocyte Count | 1 | 2022 | 246 | 0.200 |
Why?
|
| Eosinophils | 1 | 2022 | 121 | 0.190 |
Why?
|
| HIV | 2 | 2023 | 179 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2021 | 98 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2023 | 8115 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2021 | 53 | 0.180 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 41 | 0.180 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 62 | 0.180 |
Why?
|
| Feces | 1 | 2024 | 709 | 0.180 |
Why?
|
| Ancylostomatoidea | 1 | 2020 | 59 | 0.180 |
Why?
|
| Informed Consent | 1 | 2023 | 342 | 0.180 |
Why?
|
| Anemia, Neonatal | 1 | 2020 | 8 | 0.170 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 30 | 0.170 |
Why?
|
| Phototherapy | 1 | 2020 | 34 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 304 | 0.170 |
Why?
|
| Viral Load | 1 | 2021 | 381 | 0.170 |
Why?
|
| Transgender Persons | 1 | 2020 | 60 | 0.170 |
Why?
|
| Skin | 1 | 2022 | 505 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 266 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 123 | 0.160 |
Why?
|
| Health Education | 1 | 2020 | 225 | 0.160 |
Why?
|
| Sexual Behavior | 1 | 2020 | 234 | 0.160 |
Why?
|
| Hemoglobins | 1 | 2020 | 301 | 0.160 |
Why?
|
| Public Health | 1 | 2020 | 259 | 0.150 |
Why?
|
| Decision Making | 1 | 2023 | 652 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3375 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 119 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2021 | 387 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 862 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.140 |
Why?
|
| HIV-1 | 1 | 2020 | 463 | 0.140 |
Why?
|
| Pregnancy | 2 | 2020 | 7146 | 0.130 |
Why?
|
| Female | 7 | 2024 | 65562 | 0.130 |
Why?
|
| Rural Population | 1 | 2017 | 247 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2023 | 16062 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2021 | 4703 | 0.120 |
Why?
|
| Adult | 4 | 2024 | 29032 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2017 | 529 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1101 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 752 | 0.090 |
Why?
|
| Rifampin | 2 | 2022 | 125 | 0.090 |
Why?
|
| United States | 2 | 2022 | 10660 | 0.090 |
Why?
|
| Antitubercular Agents | 2 | 2022 | 246 | 0.080 |
Why?
|
| Male | 4 | 2024 | 60173 | 0.080 |
Why?
|
| Mozambique | 1 | 2024 | 17 | 0.060 |
Why?
|
| Tanzania | 1 | 2024 | 66 | 0.060 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 13 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 6029 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 58 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 132 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2021 | 89 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2021 | 145 | 0.050 |
Why?
|
| Peru | 1 | 2020 | 45 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2021 | 279 | 0.050 |
Why?
|
| Bias | 1 | 2021 | 125 | 0.040 |
Why?
|
| Cough | 1 | 2021 | 86 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2021 | 152 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 43 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 239 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2020 | 85 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 148 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 180 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 93 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 253 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 60 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 33798 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 782 | 0.040 |
Why?
|
| Child Behavior | 1 | 2021 | 232 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1305 | 0.040 |
Why?
|
| Global Health | 1 | 2023 | 546 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 296 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 401 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 944 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 1473 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1588 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1497 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 786 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 743 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2397 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 13904 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 26015 | 0.010 |
Why?
|